$NVS News
Last published 1w ago
- 1w agoGMABABBVMRKJNJ+4A little-known biotech’s high-stakes cancer bet just paid off and its shares doubledCNBCGenmab’s shares have doubled in three months after a string of cancer drug trial wins, strengthening its push to own more of the medicines it develops.
- 1w agoNVSApproval of Lamprene, Nda #019500 (Labeling)FDA Approved DrugsApproval Date: 11/03/2026; Drug Name: Lamprene, Nda #019500; Active Ingredients: CLOFAZIMINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 019500
- 1w agoBSBRMSFTAMZNGOOGL+3Companies promised AI gains— here's how the payoff showed up in earningsCNBCSantander, Novartis and other companies say AI is beginning to boost revenue, cut costs or improve profitability as investors seek returns.
- 1w agoNVSXPHA pharma giant is moving past one patent cliff — but another is already loomingCNBCDisappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
- 2w agoNVSApproval of Piqray, Nda #212526 (Labeling)FDA Approved DrugsApproval Date: 10/28/2026; Drug Name: Piqray, Nda #212526; Active Ingredients: ALPELISIB; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 212526
- 2w agoNFLXMSFTGMNVSWho’s really in charge at Anthropic after the IPO?TechCrunch
- 2w agoMSFTNVSTech's relief rally extends as attention turns to tough decisions for the FedCNBCHere are the key things investors need to know to start the trading day.
- 1mo agoNVSApproval of Rhapsido, Nda #218436 (Efficacy)FDA Approved DrugsApproval Date: 10/06/2026; Drug Name: Rhapsido, Nda #218436; Active Ingredients: REMIBRUTINIB; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218436
- 1mo agoNVSNVOAZN-GBGSK+3Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar dealsCNBCWestern biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.
- 1mo agoNVSApproval of Scemblix, Nda #215358 (Labeling)FDA Approved DrugsApproval Date: 09/22/2026; Drug Name: Scemblix, Nda #215358; Active Ingredients: ASCIMINIB HYDROCHLORIDE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215358
- 1mo agoNVSApproval of Zortress, Nda #021560 (Labeling)FDA Approved DrugsApproval Date: 09/16/2026; Drug Name: Zortress, Nda #021560; Active Ingredients: EVEROLIMUS; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021560
- 2mo agoNVSNTHITNONIRDBig Pharma Setbacks Create a New Wave of Rebound PlaysGlobeNewswireDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: even a fundamentally strong company can get caught in the crossfire when a major drugmaker
- 2mo agoQNTMNVSMRKTGTX+1Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics MarketGlobeNewswireAUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the
- 2mo agoGEBAHOODAFRM+10Jim Cramer says investors are too focused on AI stocks. Here’s where he says to look insteadCNBCCNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market.
- 2mo agoSDZ-CHNVONVS'Patients pay the tariff': Swiss pharma CEO warns of Trump's generic drug tariff threatCNBCSandoz CEO Richard Saynor warns steep U.S. tariffs on imported generic drugs could force manufacturers to raise prices or cut supply.
- 2mo agoNVSPharma major plummets over 10% after third trial disappointment in a weekCNBCShares of Novartis tanked on Tuesday after results from its del-desiran drug trial disappointed investors.
- 2mo agoNVSIONSAMGNLLY+1Cholesterol drug setback casts doubt over multibillion-dollar raceCNBCNovartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
- 2mo agoNVSApproval of Leqvio, Nda #214012 (Labeling)FDA Approved DrugsApproval Date: 08/19/2026; Drug Name: Leqvio, Nda #214012; Active Ingredients: INCLISIRAN SODIUM; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 214012
- 3mo agoNVSApproval of Myfortic, Nda #050791 (REMS)FDA Approved DrugsApproval Date: 07/29/2026; Drug Name: Myfortic, Nda #050791; Active Ingredients: MYCOPHENOLATE SODIUM; Company: Novartis; Submission Status: Approval; Submission Classification: REMS; Application Number: 050791
- 3mo agoNVSApproval of Myfortic, Nda #050791 (Labeling)FDA Approved DrugsApproval Date: 07/29/2026; Drug Name: Myfortic, Nda #050791; Active Ingredients: MYCOPHENOLATE SODIUM; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 050791
- 3mo agoNVSNovartis Q2 2026 Results Release - NovartisEarnings Call TranscriptsGood morning and good afternoon and welcome everyone to our Q2 2026 conference call. The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties and other facto
- 3mo agoNVSApproval of Tegretol, Nda #018927 (Labeling)FDA Approved DrugsApproval Date: 07/16/2026; Drug Name: Tegretol, Nda #018927; Active Ingredients: CARBAMAZEPINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 018927
- 3mo agoNVSApproval of Fabhalta, Nda #218276 (Efficacy)FDA Approved DrugsApproval Date: 07/16/2026; Drug Name: Fabhalta, Nda #218276; Active Ingredients: IPTACOPAN HYDROCHLORIDE; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218276
- 3mo agoNVSApproval of Tegretol-xr, Nda #020234 (Labeling)FDA Approved DrugsApproval Date: 07/16/2026; Drug Name: Tegretol-xr, Nda #020234; Active Ingredients: CARBAMAZEPINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 020234
- 3mo agoNVSApproval of Tegretol, Nda #016608 (Labeling)FDA Approved DrugsApproval Date: 07/16/2026; Drug Name: Tegretol, Nda #016608; Active Ingredients: CARBAMAZEPINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 016608
- 4mo agoNVSApproval of Gleevec, Nda #021588 (Labeling)FDA Approved DrugsApproval Date: 07/13/2026; Drug Name: Gleevec, Nda #021588; Active Ingredients: IMATINIB MESYLATE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 021588
- 4mo agoNVSApproval of Kisqali Femara Co-pack (copackaged), Nda #209935 (Efficacy)FDA Approved DrugsApproval Date: 07/01/2026; Drug Name: Kisqali Femara Co-pack (copackaged), Nda #209935; Active Ingredients: LETROZOLE; RIBOCICLIB SUCCINATE; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 209935
- 4mo agoNVSApproval of Kisqali, Nda #209092 (Efficacy)FDA Approved DrugsApproval Date: 07/01/2026; Drug Name: Kisqali, Nda #209092; Active Ingredients: RIBOCICLIB SUCCINATE; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 209092
- 4mo agoQNTMNVSMRKTGTX+1The Quest to Repair What Multiple Sclerosis Takes AwayGlobeNewswireAUSTIN, Texas, June 24, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Multiple sclerosis ("MS") gradually strips people of command over their own bodies, advancing steadily with no available cure.
- 4mo agoGSKNUVLXBIIBB+3Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBCCNBCBiopharma dealmaking is driven by pressure to top up drug pipelines ahead of major patent expirations later this decade.
- 5mo agoNVSApproval of Afinitor, Nda #022334 (Labeling)FDA Approved DrugsApproval Date: 06/01/2026; Drug Name: Afinitor, Nda #022334; Active Ingredients: EVEROLIMUS; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 022334
- 5mo agoNVSApproval of Sandimmune, Nda #050574 (Labeling)FDA Approved DrugsApproval Date: 05/29/2026; Drug Name: Sandimmune, Nda #050574; Active Ingredients: CYCLOSPORINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 050574
- 6mo agoNVSApproval of Mekinist, Nda #204114 (Labeling)FDA Approved DrugsApproval Date: 05/11/2026; Drug Name: Mekinist, Nda #204114; Active Ingredients: TRAMETINIB DIMETHYL SULFOXIDE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 204114
- 6mo agoNVSNovartis CEO warns reality of Trump's drug pricing policy will set in over 'the next 18 months'CNBCNovartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
- 6mo agoNVSAMGNLLYPharma bets a little-known cholesterol will underpin its next blockbuster heart drugsCNBCNovartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
- 7mo agoNVSApproval of Pluvicto, Nda #215833 (Labeling)FDA Approved DrugsApproval Date: 04/07/2026; Drug Name: Pluvicto, Nda #215833; Active Ingredients: LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 215833
- 7mo agoNVSApproval of Arzerra, Bla #125326FDA Approved DrugsApproval Date: 04/01/2026; Drug Name: Arzerra, Bla #125326; Active Ingredients: OFATUMUMAB; Company: Novartis; Submission Status: Approval; Application Number: 125326
- 7mo agoNVSApproval of Kesimpta, Bla #125326FDA Approved DrugsApproval Date: 04/01/2026; Drug Name: Kesimpta, Bla #125326; Active Ingredients: OFATUMUMAB; Company: Novartis; Submission Status: Approval; Application Number: 125326
- 7mo agoNVSApproval of Tafinlar, Nda #217514 (Labeling)FDA Approved DrugsApproval Date: 03/26/2026; Drug Name: Tafinlar, Nda #217514; Active Ingredients: DABRAFENIB MESYLATE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 217514
- 7mo agoNVSApproval of Mekinist, Nda #217513 (Labeling)FDA Approved DrugsApproval Date: 03/26/2026; Drug Name: Mekinist, Nda #217513; Active Ingredients: TRAMETINIB; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 217513
- 7mo agoNVSApproval of Tafinlar, Nda #202806 (Labeling)FDA Approved DrugsApproval Date: 03/26/2026; Drug Name: Tafinlar, Nda #202806; Active Ingredients: DABRAFENIB MESYLATE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 202806
- 8mo agoNVSApproval of Sandimmune, Nda #050625 (Labeling)FDA Approved DrugsApproval Date: 03/09/2026; Drug Name: Sandimmune, Nda #050625; Active Ingredients: CYCLOSPORINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 050625
- 8mo agoNVSApproval of Sandimmune, Nda #050573 (Labeling)FDA Approved DrugsApproval Date: 03/06/2026; Drug Name: Sandimmune, Nda #050573; Active Ingredients: CYCLOSPORINE; Company: Novartis; Submission Status: Approval; Submission Classification: Labeling; Application Number: 050573
- 8mo agoNVSNovartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategyGlobeNewswireAdds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar
- 8mo agoGMFMRKBMY+5With Trump's 'reciprocal' tariffs struck down, here are the industries still facing higher ratesCNBCPresident Donald Trump's so-called "reciprocal" tariffs were deemed unconstitutional by the Supreme Court, but some sector-specific tariffs remain in place.
- 9mo agoNVSApproval of Leqvio, Nda #214012 (Efficacy)FDA Approved DrugsApproval Date: 02/12/2026; Drug Name: Leqvio, Nda #214012; Active Ingredients: INCLISIRAN SODIUM; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 214012
- 9mo agoGILDLLYGSKABBV+6Healthy Returns: Botox, Trulicity among 15 drugs added to Medicare price negotiationsCNBCThe Trump administration kicked off another round of Medicare drug price negotiations, while Kaiser Permanente agrees to pay a historic settlement.
- 10mo agoGSKMRKBMYAMGN+7Nine of the largest pharma companies ink deals with Trump to lower drug pricesCNBCPresident Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
- 10mo agoCRMNVSSalesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement GloballyBusiness WireSalesforce (NYSE:CRM), the world's #1 AI CRM, announced today that Novartis (NYSE:NVS), a leading global innovative medicines company, has selected Salesforce's Agentforce Life Sciences for Customer Engagement to
- 11mo agoNVSApproval of Scemblix, Nda #215358 (Efficacy)FDA Approved DrugsApproval Date: 11/25/2025; Drug Name: Scemblix, Nda #215358; Active Ingredients: ASCIMINIB HYDROCHLORIDE; Company: Novartis; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 215358